The off-label use of anakinra in pediatric systemic autoinflammatory diseases

Valerio Maniscalco*, Sarah Abu-Rumeileh*, Maria Vincenza Mastrolia, Edoardo Marrani, Ilaria Maccora, Ilaria Pagnini and Gabriele Simonini

Abstract: Interleukin 1 (IL-1), a central mediator of innate immunity, is considered a master cytokine of local and systemic inflammation. IL-1 has emerged as pivotal in the pathogenesis of autoinflammatory diseases (AIDs), and blockade of its pathway has become a crucial target for therapy. Anakinra (ANA), a recombinant IL-1β receptor antagonist, was the first anti-IL-1 agent employed in clinical practice. ANA is currently approved for the treatment of rheumatoid arthritis, systemic juvenile idiopathic arthritis, adult-onset Still’s disease, and cryopyrin-associated autoinflammatory syndrome. It has also been successfully used for off-label treatment of various monogenic, polygenic, or undefined etiology systemic AIDs. This review describes currently available evidence for the off-label use of ANA in pediatric rheumatologic diseases. Specifically, the use of ANA in Kawasaki disease, idiopathic recurrent pericarditis, Behçet disease, monogenic AIDs, undifferentiated AIDs, chronic non-bacterial osteomyelitis, macrophage activation syndrome, and febrile infection-related epilepsy, in terms of its safety and efficacy. In selected pediatric rheumatic disorders, the off-label administration of ANA appears to be effective and safe. In order to control severe and/or relapsing disease, ANA should be considered as a valuable treatment option in children suffering from rare inflammatory diseases. However, currently available data consist of retrospective studies and short case series; thus, randomized controlled trials and larger series with long-term follow up are mandatory to better assess the efficacy and cost effectiveness of ANA in these challenging patients.

Keywords: anakinra, anti-IL-1 inhibitors, autoinflammatory diseases, children, interleukin-1

Received: 22 April 2020; revised manuscript accepted: 26 August 2020.
canakinumab (an anti-IL-1β immunoglobulin), rilonacept (a dimeric fusion protein that binds the extracellular domains of IL-1α and IL-1β), and anakinra (ANA) [a recombinant IL-1 receptor antagonist (IL-1RA)]. Canakinumab is approved for the treatment of cryopyrin-associated autoinflammatory syndrome (CAPS), tumor-necrosis-factor-receptor-associated periodic syndrome (TRAPS), hyperimmunoglobulinemia D syndrome/mevalonate kinase deficiency (HIDS/MKD), colchicine-resistant familial Mediterranean fever (FMF), systemic juvenile idiopathic arthritis (sJIA), and adult-onset Still’s disease (AOSD). Rilonacept is approved for the therapy of CAPS. ANA, the first licensed anti-IL-1 agent, is currently approved for the treatment of CAPS, rheumatoid arthritis, sJIA, and AOSD. However, it has also been successfully used off-label for the treatment of various monogenic, polygenic, or undefined etiology systemic AIDs. This review reports currently available evidence on the off-label use of ANA in pediatric rheumatology, including its off-label use in Kawasaki disease (KD), idiopathic recurrent pericarditis (IRP), Behçet disease (BD), monogenic AIDs, undifferentiated AIDs (uAIDS), chronic non-bacterial osteomyelitis (CNO), macrophage activation syndrome (MAS), and febrile infection-related epilepsy (FIRES), in terms of its safety and efficacy.

Kawasaki disease
KD is an acute inflammatory vasculitis of the medium and small-sized arteries, generally occurring in children under 5 years of age. It is associated with the development of coronary artery aneurysms (CAAs) or ecstasies (i.e. dilatation of an arterial vessel whose dimensions do not exceed 50% of the caliber of the vessel itself) in 15–25% of untreated children. Cardiac involvement is the main determinant of the long-term prognosis of KD patients, as coronary lesions may lead to ischemic heart disease and sudden death. The etiopathology remains unknown, though it is widely accepted that KD results in an important inflammation cascade triggered by unknown infectious or other stress triggers in a genetically predisposed individual. A single infusion of 2g/kg of intravenous immunoglobulin (IVIG) along with aspirin has reduced CAA frequency from 25% to 5%. However, 10–20% of patients do not respond to standard treatment and have an increased risk of cardiac complications and death.

As in monogenic AIDs, IL-1 seems to play a key role in the physiopathology of KD and, more importantly, in cardiac involvement and the development of CAA leading to the potential use of IL-1 blockade in patients with refractory KD.

Alphonse et al. showed a significantly increased level of IL-1β, IL-18, and of their antagonists (IL-1RA and IL-18BP) in acute KD patients compared with age-matched control patients with viral or bacterial infections. In a microarray study of acute and convalescent whole-blood samples from 146 KD subjects, KD transcript profiles showed an abundance of transcripts related to the NLRP3 inflammasome, IL-1α and β, and caspase-1 compared with pediatric subjects with different acute infectious diseases, and with healthy controls.

Early studies determined that IVIG treatment was associated with a reduction in IL-1β secretion from KD patients without CAA versus persistently elevated levels in IVIG-treated patients with CAA. It is well known that IVIG resistance is associated with coronary vasculitis, and IVIG-resistant KD patients have decreased expression of IL-1RA. Genetic studies have also identified that polymorphisms of inositol 1,4,5-trisphosphate 3-kinase C (ITPKC) represent a susceptibility factor for KD and CAA. The ITPKC gene induces increased Ca2+ flux into the cell, NLRP3 inflammasome activation, and increased secretion of IL-1β and IL-1α.

Moreover, in a Lactobacillus casei cell-wall-extract-induced mouse vasculitis model, ANA administration was able to prevent aortic aneurysms and to improve cardiac ejection fraction by controlling myocarditis, suggesting that early use of ANA might better prevent or treat early coronary lesions.

Similar successful results were confirmed in the clinical setting of refractory KD as well as in MAS caused by KD responsive to ANA treatment (Table 1).

Kone-Paut et al. recently published a case series of 11 children with refractory KD and cardiac complications who received ANA. All patients became afebrile and achieved significant decreases of inflammatory markers within a few days after administration of ANA, although the reported results on its effect on coronary dilations are heterogeneous.

Considering the upregulation of the IL-1 pathway in KD, ANA may represent a valuable
therapeutic tool to control systemic inflammation in KD patients. The convergence of genetic data and results from animal models provide a strong rationale for the hypothesis that IL-1 signaling plays a key role in KD vasculitis and coronary arteritis; in this perspective, ANA may also have a role in preventing the onset of CAA, especially if used at diagnosis. In this regard, two clinical trials of ANA involving KD pediatric patients are currently underway in western Europe and the United States: the Kawakinra trial [Eudract no: 2014-002715-41]; and the ANAKID trial [ClinicalTrials.gov identifier: NCT02179853], respectively. The outcomes of these studies may better define the place of IL-1 blockade in KD treatment in association with or in replacement of IVIG and steroids.

### Table 1. Main studies reporting anakinra administration in Kawasaki disease.

| Type of study | Patients (n) | Dose | Response | Adverse events | Follow up (days) |
|---------------|--------------|------|----------|----------------|-----------------|
| Cohen et al. 2012 | Case report 1 | 1 mg/kg/day | Remission | NA | 180 |
| Shafferman et al. | Case report 1 | 6 mg/kg/day for 2 days, 9 mg/kg/day for 3 days | Failure in preventing CAA | NA | 240 |
| Guillame et al. | Case report 1 | 6 mg/kg/day for 10 weeks, 6 mg/kg/day every 2 days for 4 weeks, 6 mg/kg/day every 3 days for 4 weeks | Remission of fever and decrease of APPs, partial CCA regression | None | 126 |
| Sanchez-Manubens et al. | Case report 1 | 2 mg/kg/day | Complete remission | None | 112 |
| Blonz et al. | Letter to the editor 1 | 100 mg/day | Complete remission | NA | 330 |
| Kone-Paut et al. | Retrospective 11 | 2–7.5 mg/kg/day | Remission of fever and decrease of APPs, not determined effect on CAA | NA | 6–81 |
| Lind-Holst et al. | Case report 1 | 5 mg/kg/day and then 10 mg/kg/day | Remission after dose increment | NA | 480 |

APPs, acute-phase proteins; CAA, coronary artery aneurysm; NA, not available.

**Idiopathic recurrent pericarditis**

Recurrent pericarditis is a relatively common complication (15–30%) of acute pericarditis. In the majority of patients with recurrent pericarditis (70–80%) no specific cause is identified and the disease is referred to as IRP. Established therapeutic regimens, such as non-steroidal anti-inflammatory drugs (NSAIDs), colchicine, and steroids, induce remission in most cases. Nevertheless, a subset of patients either do not respond, relapse, or cannot tolerate the standard therapeutic interventions. In this perspective, IRP shares many features consistent with AIDs. Indeed, recurrent episodes of apparently unprovoked inflammation and serosal involvement are characteristic of AIDs and it is well known that FMF and TRAPS can sometimes present with isolated serosal involvement, especially when the onset is in adulthood. In line with this hypothesis, Cantarini et al. found that 6% of IRP patients carry a mutation in the tumor necrosis factor (TNF) receptor superfamily member 1A (TNFRSF1A) gene. Hence, biological agents are emerging as potential therapeutic options for the treatment of IRP, with the majority of experiences having been acquired with ANA. Considering the adverse impact of steroids in pediatric patients, treatment with ANA in this patient population was primarily taken into account (Table 2).

In 2009, Picco et al. described the first small series of three pediatric subjects suffering from steroid-dependent IRP treated with ANA with an
immediate clinical and laboratory response.\textsuperscript{25} Pericarditis recurred when treatment was discontinued, and no relapses occurred after ANA was resumed. Subsequently, two further case reports have described the success of ANA therapy in IRP adolescents.\textsuperscript{29,30}

A retrospective, multicentric evaluation of ANA efficacy both in children (\(n = 12\)) and adults (\(n = 3\)) with IRP showed a clinical and laboratory response in all patients with the concurrent withdrawal of steroid treatments.\textsuperscript{31} During an attempt to taper treatment, approximately half of the patients experienced a flare, promptly controlled by ANA re-introduction. Moreover, during the follow-up period (median 39 months), a reduction of around 95\% of relapses was observed compared with the pre-treatment period. In a large multicenter cohort study of 110 consecutive cases of IRP pediatric patients, ANA therapy was prescribed to 12 children.\textsuperscript{33} In this subgroup, the number of recurrences dropped from 4.29 per year before ANA to 0.14 per year after (\(p < 0.05\)).

In the ANA Treatment of Recurrent Idiopathic Pericarditis (AIRTRIP) randomized controlled trial that enrolled 20 adult patients and 1 pediatric patient, ANA reduced the risk of recurrence over a median of 14 months compared with placebo.\textsuperscript{32} The management of ANA discontinuation after remission remains controversial. Despite a lack of solid evidence, most experts recommend a gradual dose tapering. In a systematic review, Lazaros et al. recorded a 26\% relapse rate during dose tapering or after drug discontinuation in 34 pediatric and adult patients with IRP successfully treated with ANA.\textsuperscript{28}

### Behçet disease

BD is a multisystem inflammatory disorder characterized by variable involvement of the oral and genital mucosa, skin and eyes, and by a relapsing–remitting clinical course. The clinical spectrum includes mucocutaneous lesions (aphthous ulcers on the oral and/or genital mucosa, erythema nodosum, and other heterogeneous skin lesions), arthritis, eye involvement, vascular manifestations, gastrointestinal, and central nervous system involvement. The epidemiology of BD is strictly linked to the historical route of the Silk Road, with the highest incidence in Turkey and other Middle East countries, where an overall prevalence of 1 in 250 persons has been reported.\textsuperscript{34} Most patients are diagnosed in young adulthood, although onset before the age of 16 is seen in 4–26\% of cases.\textsuperscript{35} The etiology remains unknown, but dysregulation of both innate and adaptive immunity is supposed.

| Type of study          | Patients (\(n\)) | Dose                      | Response                                      | Adverse events | Median follow up (months) |
|------------------------|------------------|---------------------------|-----------------------------------------------|----------------|--------------------------|
| Picco et al.\textsuperscript{25} | Case series      | 3                         | 1 mg/kg/day                                   | Remission, Relapse after discontinuation | NA            | 4.2 (range 4–6)          |
| Scardapane et al.\textsuperscript{29} | Case report      | 1                         | 100 mg/day, Month 10 at alternate days         | Remission      | None                     | 12                   |
| Camacho-Lovillo et al.\textsuperscript{30} | Case report      | 1                         | 2 mg/kg/day                                   | Remission, relapse after discontinuation | NA            | 36                     |
| Finetti et al.\textsuperscript{31} | Retrospective    | 12                        | Starting dose of 1.3 mg/kg/day (range 1–2 mg/kg/day) | Remission, 5 patients off therapy | Local injection-site reaction | 34.5 (range 14–57)   |
| Imazio et al.\textsuperscript{23} | Retrospective    | 12                        | 1 mg/kg/day                                   | Remission      | NA                       | NA                   |
| Brucato et al.\textsuperscript{32} | Randomized controlled trial | 1                         | 2 mg/kg/day                                   | Remission      | NA                       | 12                   |

NA, not available.
Recently, growing evidence supports the hypothesis of an autoinflammatory component in the pathogenesis of BD. Even if BD is typically considered a polygenic disorder with a predominant role for the sub-allele HLA-B51, a connection between the AIDs and BD is supported by the discovery of a hereditary ‘Behçet-like’ inflammatory syndrome. This rare condition, due to a mutation in the A20/TNFAIP3 gene, results in A20 protein haploinsufficiency causing a reduced suppression of nuclear-factor kappa B (NF-κB) activation and an abnormally increased inflammatory response. Another similarity with AIDs is given by successful IL-1 inhibition in BD patients. Evidence from adult patients suggests that anti-IL-1 agents might be useful in the treatment of the most severe manifestation, unresponsive to conventional treatment with colchicine, steroids, or immunosuppressant drugs. IL-1 antagonists, in particular ANA, are used off-label in both pediatric and adult patients; a survey among Italian physicians reported that ANA accounted for almost 10% of all off-label prescriptions during the period 2008–2016.

A recent systematic review suggested that IL-1 inhibitors may represent an effective therapeutic option, even if most of the data come from a limited number of observed patients. Bettiol et al. reported that ANA could be used effectively to control mucocutaneous symptoms and osteoarticular manifestations in BD patients and may represent an effective and safe therapeutic option for BD-related uveitis. As for the use of anti-IL-1 treatments in the pediatric population, discrepant evidence was found, and the data are extremely limited (Table 3). In a case series of patients with BD resistant to standard therapy, Cantarini et al. described the case of a 7-year-old boy treated with ANA at a dosage of 2 mg/kg for BD non-responsive to prednisolone, colchicine, thalidomide, and mycophenolate mofetil. The patient improved with the disappearance of systemic and mucocutaneous manifestations and steroid tapering. After 4 months, he experienced a disease relapse with abdominal pain, bipolar aphthosis, skin ulcers, and arthralgias. ANA dosage was subsequently increased to 2.5 mg/kg/day; clinical manifestations improved in frequency and intensity, although he still complained of severe oral aphthosis, abdominal distress, headache, and skin ulcers after 7 months.

The efficacy of ANA treatment has also been reported in a girl suffering from BD associated with FMF and will be described in detail in the next section. Unsuccessful ANA treatment was reported in a letter by Ugurlu et al., who described persistent ocular inflammation despite treatment in a 16-year-old girl. In another retrospective observational study, use of ANA in a child was associated with a partial response. A higher dose of ANA may be efficacious in subjects initially unresponsive to the standard dosage, and may lead to complete remission. However, an overall excellent safety profile has been reported in the literature and recently confirmed in two multicenter observational cohort studies including both pediatric and adult patients, which specifically evaluated side effects in BD patients treated with biologic agents.

**Familial Mediterranean fever**

FMF is an autosomal-recessive AID characterized by recurrent attacks of fever and serositis. AA amyloidosis represents the main cause of mortality, which may complicate the disease due to persistent unremitting inflammation. Colchicine represents the milestone of FMF treatment, despite 10–15% of patients being either colchicine resistant or intolerant. Therefore, in such cases, additional or alternative treatment is required. The proof that FMF pathogenesis is driven by the overexpression of IL-1β justified the blockade of IL-1 as a potential target therapy. In this regard, canakinumab has recently been approved in resistant FMF, whereas ANA remains an off-label indication in pediatric patients. Most of the available literature refers to retrospective studies and short case series. However, the efficacy of ANA is widely described in adult patients, in both systematic literature reviews and in randomized controlled trials. Hence, considering its efficacy and safety, ANA represents a valuable treatment option in resistant/intolerant FMF patients, including pediatric patients.

Two case reports by Kuijk et al. and Calligaris et al. described a complete remission in adolescents with FMF, unresponsive to colchicine therapy. The first reported case described a 14-year-old patient that, after ANA administration, became free from
Therapeutic Advances in Musculoskeletal Disease 12

Disease attacks with normalization of C-reactive protein values. The patient also reported a marked improvement in quality of life and depressive symptoms.\(^{36}\) Subsequently, in a larger pediatric series which demonstrated the efficacy and safety of ANA in achieving disease control, Ozen et al. reported a 60% rate of remission without adverse events in five pediatric patients with recurrent attacks despite optimal compliance to colchicine.\(^{60}\) As observed in adult patients, ANA proved effective in restoring serum amyloid A levels to normal ranges as well as in reversing proteinuria and controlling disease progression in patients with secondary amyloidosis. Bilgner et al. reported the case of an 8-year-old girl with FMF and BD, complicated by secondary amyloidosis, who achieved clinical and biochemical remission after 6 months of therapy with ANA.\(^{41}\) She remained asymptomatic, despite a gradual increase in proteinuria at the 18-month follow up.

In a cohort of seven pediatric FMF patients, four of whom had secondary amyloidosis, disease remission was achieved in all children with normalization of acute-phase reactants and regression of amyloidosis-related gastrointestinal findings.\(^{61}\) One child with nephrotic syndrome achieved partial remission after 12 months. In two patients with chronic kidney disease and one with renal transplantation, the decline in renal function was interrupted.

Stronger evidence is derived from a larger series including 49 FMF patients, both pediatric and adult, 20 of whom received ANA.\(^{75}\) Fourteen patients received ANA as a first biologic regimen, with a reported complete response rate of 50% (7/14), whereas biochemical control was achieved in 43% (6/14) of patients.

**Tumor-necrosis-factor-receptor-associated periodic syndrome**

TRAPS is the most common autosomal-dominant AID, characterized by recurrent attacks of prolonged fever, typically lasting several weeks, associated with different clinical manifestations including serositis, migratory rash, and ocular inflammation.\(^{76}\) Many aspects of its pathogenesis remain unclear. However, there is evidence suggesting that an altered three-dimensional shape of TNFRSF1A leads to an increased production of pro-inflammatory cytokines and systemic inflammation through not completely clarified pathomechanisms. Among these, impaired TNFα binding, altered NF-κB pathway, abnormal neutrophilic TNFα-induced apoptosis, as well as defective TNFRSF1A trafficking have been described.\(^{77,78}\) NSAIDs could partially relieve symptoms and on-demand steroids usually block the attacks, but their efficacy decreases over time and a longstanding administration may cause the well-known side effects.\(^{79}\) Moreover, these patients have an increased risk of AA amyloidosis. Based on a supposed TNFα-driven pathogenic mechanism, etanercept was administered in these patients without significant and longlasting efficacy.\(^{80}\) Conversely, IL-1 blockade can control systemic inflammation in TRAPS. Canakinumab has been recently validated through two open-label studies demonstrating IL-β blockade superiority in achieving disease remission, compared with placebo.\(^{81,82}\) ANA remains off-label due to the lack of available randomized controlled trials, despite its widespread use in both adult and pediatric patients. Indeed, ANA has been demonstrated to induce rapid disease remission and prevent relapse. In the pediatric field (Table 4), the first study reporting data on ANA efficacy included four children affected by TRAPS with a

| Type of study | Patients (n) | Dose | Response | Adverse events | Follow up (months) |
|---------------|-------------|------|----------|---------------|-------------------|
| Bilgner et al.\(^{41}\) | Case report 1 (also affected by FMF) | 1 mg/kg/day | Remission | NA | 18 |
| Urgulu et al.\(^{42}\) | Letter to the editor | 2 mg/kg/day | Persistent uveitis | NA | 1 |
| Cantarini et al.\(^{40}\) | Case series | 2 mg/kg/day and after 4 months 2.5 mg/kg/day for a relapse | Partial response | NA | 9 |

FMF, familial Mediterranean fever; NA, not available.

---

**Table 3. Main studies reporting anakinra administration in pediatric Behçet disease.**

---

6 journals.sagepub.com/home/tab
| Type of study | Patients (n) | Dose OD (n) | CR* | PR** | Adverse events | Median follow up (months) |
|---------------|--------------|-------------|-----|------|----------------|--------------------------|
| **FMF**       |              |             |     |      |                |                          |
| Kuijk et al.  | 1            | 100 mg/day  | 100%| –    | Mild urticarial rash | NA                      |
| Calligaris et al. | 1   | 1 mg/kg/day | 100%| –    | Local injection site reaction | 18                      |
| Roldan et al. | 1            | 1 mg/kg/day | 100%| –    | None           | 6                       |
| Ozen et al.   | 5            | 1–2 mg/kg/day | 60% | 40%  | NA             | 9 (range 2–30)          |
| Meinzer et al. | 4   | 1–2 mg/kg/day | 100%| –    | Local injection site reaction | 6.5 (range 4–16) |
| Cetin et al.  | 2            | 1–1.5 mg/kg/day | 100%| –    | None           | 9.5 (range 7–12)        |
| Özçakar et al.| 7            | 1 mg/kg/day  | 71% | 19%  | None           | 15 (range 9–40)         |
| **TRAPS**     |              |             |     |      |                |                          |
| Gattorno et al. | 4   | 1.5 mg/kg/day | 100%| –    | Local injection site reaction | 11.4 (range 4–20) |
| Grimwood et al. | 2  | 2 mg/kg/day | 100%| –    | Local injection site reaction | NA                     |
| **MKD/HIDS**  |              |             |     |      |                |                          |
| Rigante et al.| 1            | 1 mg/kg/day  | –   | 100% | Local injection site reaction | 18                      |
| Nevyjel et al.| 1            | 30 mg/day    | –   | 100% | NA             | 12                      |
| Korppi et al. | 1            | 2 mg/kg/day  | 100%| –    | None           | 6                       |
| Bodar et al.  | 2            | 1–2 mg/kg/day | 50% | 50%  | Local injection site reaction | NA                     |
| Galeotti et al.| 5  | 1–5 mg/kg/day | 20% | 80%  | Local injection site reaction, bacterial pneumonia | 13*** (range 2–39) |
| **uAIDs**     |              |             |     |      |                |                          |
| Shendi et al. | 1            | 100 mg/day   | 0%  | 0%   | Prolonged fever | 5 days                  |
| Levy et al.   | 2            | 2–3 mg/kg/day | 50% | 50%  | NA             | 6.5 (range 6–7)         |
| Campanilho- Marques | 2 | 2–6 mg/kg/day | –   | 100% | Herpes zoster infection | 12 (range 7–17) |
| Santos et al. | 1            | 2–5 mg/kg/day | –   | 100% | None           | 36                      |
| Kostjukovits et al. | 3 | 2 mg/kg/day | 33% | 67%  | None           | 36 (range 24–48) |
| **APPs, acute-phase proteins; APRs, acute-phase reactants; CR, complete response; FMF, familial Mediterranean fever; HIDS, hyperimmunoglobulinemia D syndrome; MKD, mevalonate kinase deficiency; NA, not available; OD, on demand; PR, partial response; TRAPS, tumor-necrosis-factor-receptor-associated periodic syndrome; uAIDs, undifferentiated autoinflammatory diseases.** | **Table 4. Main studies reporting anakinra administration in pediatric FMF, TRAPS, HIDS and uAIDs.** |
Therapeutic Advances in Musculoskeletal Disease 12

Mevalonate kinase deficiency
MKD is an extremely rare, autosomal-recessive AID, caused by mutations in the gene encoding mevalonate kinase (MVK) that lead to a partial enzyme deficiency. MKD, also known as HIDS, shows a less severe phenotype compared with mevalonic aciduria (MVA), a disease with a critical MVK deficiency causing neurological involvement. The enzyme defect interferes with the mevalonate pathway and cholesterol synthesis, and is responsible for IL-1β overproduction and systemic inflammation. The typical clinical phenotype is characterized by recurrent attacks of fever lasting 3–7 days, associated with inflammatory symptoms such as lymphadenopathy, arthralgia, mucocutaneous, and gastrointestinal manifestations. NSAIDs and high-dose steroids are usually administered to relieve symptoms and reduce the duration of attacks. Among biologic agents, those targeting IL-1 are the most effective. In a cohort of 38 MKD pediatric and adult patients treated with biologic therapies, ANA was administered in 68% of cases as first-line therapy. Further case reports have confirmed ANA efficacy in children. Moreover, a series of five pediatric patients was retrospectively described by Galeotti et al. (Table 4). In this study, ANA was administered daily in four patients and on demand in one patient, achieving complete and partial remission in 40% (2/5) and 60% (3/5) of patients, respectively. In addition, a review of 21 pediatric patients treated with ANA observed a complete remission rate of 19% (4/21) and a partial remission rate of 71% (15/21). Limited side effects were described, namely local injection-site reactions, bacterial pneumonia, and herpes zoster infection. Similar results were derived from a series including 27 adult and pediatric MKD patients treated with ANA: efficacy was reported in 89% of patients, with complete remission in 22%. The coexistence with another disease, specifically early-onset ulcerative colitis and membranoproliferative glomerulonephritis, has been reported in two cases. Both patients were successfully treated with ANA and experienced a favorable control of MKD manifestations, as well as of the associated disease symptoms. Among pediatric studies, the case of a 10-year-old patient who experienced more prolonged and severe attacks under ANA, with rapid clinical improvement after discontinuation, is of note.

Undifferentiated autoinflammatory diseases
Patients who fulfill the clinical features of AIDs but have negative genetic screening for FMF, CAPS, TRAPS, or MKD, are defined as affected by uAIDs. Harrison et al. reported the efficacy of ANA administration in 9 of 11 uAID adult patients who were unresponsive to standard steroid/disease-modifying antirheumatic drug (DMARD) treatments. Moreover, in a series of 22 pediatric patients retrospectively described by Garg et al., 72% of uAID children showed clinical improvement after ANA administration, with 36% achieving full remission within 3 months. The efficacy of ANA has emphasized the implication of IL-1 dysregulation in the pathogenesis of uAID. Empirical trials of IL-1 blockade in uAID patients may be warranted, as long as advances in next-generation sequencing technologies can determine appropriate target therapies. In this study, ANA was well tolerated overall, and, unlike...
previous studies, the most common adverse event was infection, not local injection-site reaction (Table 4).

**Chronic non-bacterial osteomyelitis**

CNO is a group of autoinflammatory bone disorders typically affecting pediatric patients and characterized by accelerated bone remodeling and inflammatory bone loss.\(^{86}\) The pathogenesis of CNO seems to be driven by IL-1 pathway over-activation and under-expression of the IL-10 family of cytokines.\(^{87}\) The clinical spectrum ranges from asymptomatic localized bone inflammation to severe and disseminated forms. The most severe phenotype is represented by chronic, recurrent multifocal osteomyelitis (CRMO), characterized by bone pain and joint swelling potentially involving any skeletal site.\(^{86}\) There are no validated treatments due to the rarity of the disorder. NSAIDs or high-dose steroids are prescribed as first-line therapies, depending on disease severity. When a response cannot be obtained, anti-TNFα agents and bisphosphonates are considered alternative regimens.\(^{86}\) In patients refractory to such treatments, ANA appears to be a promising and safe option (Table 5).

The first report on the efficacy of ANA in CNO described the case of a 6-year-old girl with a recalcitrant disease unresponsive to NSAIDs, steroids, and bisphosphonates.\(^{89}\) ANA was started, following the detection of high levels of circulating IL-1RA. After 6 weeks the symptoms resolved, and the inflammatory markers normalized. Unfortunately, remission was not sustained at the 1-year follow up, and, after a recalcitrant course, ANA was discontinued 3 years later.

In a retrospective analysis of 486 patients, including 455 pediatric CNO, ANA was administered in four children, showing a complete remission in two patients, and a partial response or no response in one patient each.\(^{86}\) The largest pediatric CNO series by Pardeo et al. described nine patients with refractory disease treated with ANA.\(^{88}\) The response was evaluated through the Physician Global Assessment (PGA) scoring system, which included fever, functional impairment, inflammatory markers, and bone scintigraphy lesions. At baseline, all patients presented a mild-to-severe PGA and eight of nine patients had elevated inflammatory markers. After 6 months of therapy, five patients improved to a minimal or no PGA, and, in eight of nine patients, a reduction of acute-phase reactants was described, with normalization in five of them. Overall, 42 of 77 bone lesions resolved, and the remainder were stable. However, 20 new lesions appeared in 7 patients.

IL-1 targeting also demonstrated effectiveness in Majeed syndrome and deficiency of IL-1 receptor antagonist (DIRA) syndrome. Majeed syndrome is an autosomal-recessive disorder, caused by mutations in the \(LPIN2\) gene and characterized by recurrent fever and the typical triad of CRMO, congenital dyserythropoietic anemia, and neutrophilic dermatosis.\(^{90,91}\) CRMO starts during infancy causing, if not recognized and treated, retarded growth, permanent joint contractures, and bone deformities. Steroids partially improve the bone and skin disease, whereas ANA can rapidly control systemic inflammation. Herlin et al. reported the case of a 2-year-old child with Majeed syndrome who was successfully treated with ANA for 6 weeks with prompt clinical and laboratory improvement, despite a rapid relapse after therapy discontinuation.\(^{90}\)

DIRA is an autosomal-recessive disease caused by the absence of the IL-1 receptor, characterized by neonatal onset and life-threatening inflammation.

| Type of study      | Patients (n) | Dose       | CR* | PR** | Adverse events | Median follow up (months) |
|--------------------|--------------|------------|-----|------|----------------|--------------------------|
| Pardeo et al.\(^{89}\) | Retrospective 9 | 2–2.3 mg/kg/day | 0%  | 89% (8/9) | None          | 20.4 (range 9.6–33.6)    |
| Eleftheriou et al.\(^{88}\) | Case report 1 | 2 mg/kg/day | /   | 100% | None          | 12           |

*C defined as no symptoms and radiological resolution of all bone lesions and no appearance of new bone lesions.

**PR defined as symptoms improvement and/or decrease of radiological bone lesions.

CNO, chronic non-bacterial osteomyelitis; CR, complete response; NA, not available; PR, partial response.
The disease occurs within 3 weeks after birth with neutrophilic pustular rash, joint swelling, and oral mucosal lesions. The multifocal bone involvement leads to balloon-like widening of the ribs, periosteal elevation of long bones, and multiple osteolytic lesions. Therapy with DMARDs and high-dose steroids can only partially control the clinical manifestations, whereas ANA has been demonstrated as highly effective in determining a complete resolution of symptoms and normalization of inflammatory markers.

Macrophage activation syndrome

MAS is a potentially fatal complication of several rheumatic disorders. The definition of MAS is applied to secondary hemophagocytic lymphohistiocytosis (sHLH) in the context of rheumatic diseases. In the pediatric age, sJIA is by far the disease most frequently complicated by MAS. However, in several reports the occurrence of MAS has been described during the course, or as revealing manifestation of AIDs (i.e. in CAPS, MKD, FMF and TRAPS), resulting in a severe complication with high morbidity and mortality rates.

MAS is a unique clinical syndrome characterized by fever, organomegaly, cytopenia, and organ involvement up to multiple organ failure. Laboratory abnormalities include a decrease in white blood cells, platelet and hemoglobin, hypertransaminasemia, marked increase in ferritin, and evidence for intravascular coagulation activation. Uncontrolled activation and proliferation of T lymphocytes and macrophages are the typical immunological features.

Since 2008, several studies showed favorable results following ANA administration in patients affected by MAS unresponsive to conventional treatments (i.e. steroids, cyclosporin, IVIG) (Table 6). In this regard, Miettunen et al. described the achievement of clinical and biochemical remission with ANA in 12 patients with MAS (including five patients who required intensive care support) after the failure of treatment with steroids and other immunosuppressants. Moreover, all patients experienced a good control of the underlying rheumatic diseases at follow up (Table 6).

In most of the available studies, ANA was administered at the standard dosage (1–2 mg/kg/day). The response to treatment appears rapid and without significant side effects; only one case reported pain at the injection site. However, a higher dose of ANA (ranging from 4 mg/kg/day to 15 mg/kg/day) was required to achieve remission in other studies, especially in the case of MAS associated with KD.

While most of the patients received ANA in association with steroids, IVIG, or immunosuppressive drugs, monotherapy seems to be promising in patients affected by sJIA developing MAS. A recent retrospective study demonstrated that an earlier introduction of ANA treatment, within 5 days of MAS onset, was associated with reduced mortality, especially when sJIA represents the underlying diagnosis.

ANA treatment is not only limited to rheumatologic patients but is also adopted in children and adults affected by infection-associated sHLH and in critically ill patients with various underlying diseases. The efficacy of IL-1 blockade in a cytokine storm was also confirmed by clinical experience in septic shock.

On the other hand, some studies reported that children with sJIA treated with ANA developed MAS. Nigrovic et al. described MAS in four patients receiving ANA, but none showed a clear causal association, and all patients could ultimately continue the therapy. The underlying active disease rather than drug administration could be the real trigger of MAS. According to the authors, ANA at 1–2 mg/kg/day was not sufficient to prevent MAS in sJIA; but once it occurred, clinical features improved after dose increase.

A double-blind, randomized controlled trial [ClinicalTrials.gov identifier: NCT02780583] is currently underway to assess the efficacy, safety, and tolerability of ANA in combination with standard prescribed treatment for children and adults with MAS.

Febrile-infection-related epilepsy syndrome

FIRES is a subtype of new-onset refractory status epilepticus. According to the consensus definitions, it is a rare catastrophic epileptic encephalopathy characterized by a preceding febrile infection between 24 h and 2 weeks before the onset of seizures. FIRES diagnosis is essentially clinical, and the syndrome should be suspected in patients of all ages. In pediatric patients, the
estimated annual incidence is 1:1,000,000, while its prevalence is 1:100,000 in previously healthy children and adolescents.\textsuperscript{117} FIRES is characterized by relentless cognitive and motor function decline and severe neurological sequelae with a high mortality rate.\textsuperscript{118} The FIRES seizure pattern is usually resistant to multiple antiepileptic drugs. Alternative treatment options such as anesthetic drugs, immunotherapy, ketogenic diet, therapeutic hypothermia, and cannabidiol have shown only partial efficacy.\textsuperscript{119–121}

Recent studies have evoked the role of IL-1β in seizure onset.\textsuperscript{122} Experimental animal models

| Table 6. Main studies reporting anakinra administration in pediatric MAS. |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| **Type of study** | **Patients (underlying disease), n** | **Dose** | **Response** | **Adverse events** | **Median follow up (months)** |
| Kelly et al.\textsuperscript{107} | Case report 1 [sJIA] | 1 mg/kg/day | Remission | None | 24 |
| Miettunen et al.\textsuperscript{106} | Case series 12 [8 sJIA, 2 VASC, 1 ARF, 1 KD] | 2 mg/kg/day | Remission | None | 22 [range 2–40] |
| Bruck et al.\textsuperscript{108} | Case series 2 [sJIA] | 2 mg/kg/day | Remission | Pain at injection site | 8 and 17 |
| Kahn et al.\textsuperscript{101} | Case report 1 [sJIA] | 1.75 mg/kg/day and then 6.7 mg/kg/day every 6 h | Remission | NA | 30 |
| Butin et al.\textsuperscript{102} | Case report 1 [PB19] | 2 mg/kg/day and then 4 mg/kg/day | Remission | NA | 2 |
| Lilleby et al.\textsuperscript{109} | Case report 1 [JDM] | 2 mg/kg/day | MAS parameters improvement | NA | 3 |
| Rajasekaran et al.\textsuperscript{110} | Retrospective study 8 [critically ill children] | 1–2 mg/kg/day increased according to clinical response | Lower mortality rate (12.5%) | None | NA |
| Shafferman et al.\textsuperscript{14} | Case report 1 [KD] | 9 mg/kg/day | MAS parameters improvement | NA | 8 |
| Aytá\textsuperscript{103} et al. | Retrospective study 15 [13 sJIA, 2 SLE] | NA | Remission | NA | NA |
| Sönmez\textsuperscript{105} | Retrospective study 19 MAS episodes in 15 patients [13 sJIA, 2 AIDs] | 2 mg/kg/day | Remission Recurrent MAS episodes after anakinra dose reduction [2/3] | Vitiligo [1/3] | 13 [range 6–24] |
| Barsalou et al.\textsuperscript{104} | Case report 1 [NLRC4 GOF mut] | 15 mg/kg/day [combination therapy with rapamycin] | Remission | NA | 12 |
| Lind-Holst et al.\textsuperscript{17} | Case report 1 [KD] | 5 mg/kg/day and then 10 mg/kg/day | Remission after dose increment | NA | 16 |
| Eloseily et al.\textsuperscript{110} | Retrospective study 44 [13 sJIA] | NA | Reduced mortality with earlier start of anakinra [≤5 days] | NA | NA |

AIDs, autoinflammatory diseases; ARF, acute rheumatic fever; JDM, juvenile dermatomyositis; KD, Kawasaki disease; MAS, macrophage activation syndrome; NA, not available; NLRC4 GOF mut, gain of function mutations affecting the inflammasome component NLRC4; PB19, parvovirus B19 infection; sJIA, systemic juvenile idiopathic arthritis; SLE, systemic lupus erythematosus; VASC, vasculitides.
support this hypothesis: IL-1β receptor-deficiency in mice seems to have a protective role against febrile seizures since high IL-1β doses induce epilepsy in IL-1β-receptor-expressing mice.\textsuperscript{123} Another study proposed that FIRES is probably associated with reduced expression or functional deficiency of the intracellular IL-1 receptor.\textsuperscript{124} This evidence justifies targeted therapy with IL-1 antagonists, especially ANA (Table 7). In the first reported case by Kenney-Jung \textit{et al.} a 32-month-old girl with super-refractory \textit{status epilepticus} despite multiple drugs and a 3-day course of high-dose methylprednisolone, was treated with ANA (5 mg/kg twice daily, subcutaneously) resulting in a progressive decrease in the frequency of recurrent seizures.\textsuperscript{125} However, relapse was experienced after ANA withdrawal. A similar clinical response was described in four of five children suffering from FIRES treated with ANA at a dose ranging from 3 mg/kg/day to 7 mg/kg/day.\textsuperscript{126} Further case reports confirmed ANA efficacy.\textsuperscript{127,128} Moreover, ANA was associated with deep brain stimulation of the centromedian thalamic nuclei in two boys, reporting a positive effect in one patient.\textsuperscript{129}

Finally, Kenney-Jung \textit{et al.} reported elevated levels of pro-inflammatory cytokines in cerebral spinal fluid before treatment that normalized after ANA administration, emphasizing a pathogenic role of autoinflammation in FIRES.\textsuperscript{125}

**Conclusion**

AIDs represent a heterogeneous group of disorders related to multiple genetic defects, including inflammasomes, proteasome, cytokine receptors or inhibitors, and different enzymes.\textsuperscript{130} In pediatric AIDs, off-label use of ANA has been widely demonstrated as effective and safe. ANA should be considered in selected children suffering from systemic inflammatory diseases who do not tolerate other therapies or who require unacceptably high doses of steroids to control a severe and/or relapsing disease course.

Clinicians should direct the choice to switch to ANA based on the AID-related damage assessment, to capture potentially irreversible disorders of structure and function. Reproducible scores to evaluate the subsequent response to therapy in an objective way and to compare patients belonging to the same clinical setting or from different cohorts are needed. In the damage assessment, therapeutic toxicity must also be considered, for example, growth retardation, weight gain, and

| Table 7. Main studies reporting anakinra administration in pediatric FIRES. |
|-------------------|-----------------|------------------|--------------------------|-----------------|-----------------|
| Type of study     | Patients (n)    | Dose             | Response                          | Adverse events                  | Follow up (months) |
| Kenney-Jung \textit{et al.}\textsuperscript{125} | Case report 1 | 5 mg/kg twice daily | Clinical and EEG improvement | None | 12 |
| Shukla \textit{et al.}\textsuperscript{126} | Case series 5 | 3–7 mg/kg/day | Clinical improvement in 4/5 patients | DRESS (2/5) mild infections (5/5) | NA |
| De Sena \textit{et al.}\textsuperscript{128} | Case report 1 | 100 mg daily and then twice daily | Clinical and EEG improvement | NA | 36 |
| Sa \textit{et al.}\textsuperscript{129} | Case series 2 | 5 or 10 mg/kg | Patient 1: refractory epilepsy with infrequent short focal seizures Patient 2: reduction in the total number of seizures, vegetative state | NA | 15 and 18 |
| Dilena \textit{et al.}\textsuperscript{127} | Case report 1 | 2.5 mg/kg twice daily; after 2 months 2.5 mg/kg/day | Clinical and EEG improvement | None | 36 |

EEG, electroencephalogram; FIRES, febrile infection-related epilepsy; NA, not available.
hypertension derived from chronic glucocorticoid consumption. In this regard, the autoinflammatory disease damage index has recently been developed for the evaluation of FMF, TRAPS, MKD, and CAPS patients.\textsuperscript{131}

ANA has a remarkable safety profile with over 150,000 patients treated daily for over 10 years.\textsuperscript{132} Since blood levels drop significantly within a few hours after discontinuation of treatment, ANA represents a manageable drug.\textsuperscript{3} In suspicion of AIDs, ANA could be considered as an empiric treatment in case of temporary contraindication to glucocorticoids for diagnostic workup, while waiting to exclude infection or malignancy.\textsuperscript{133}

However, some points need to be clarified in the near future: what kind of patients need treatment with ANA, which subgroup of patients could receive ANA as first-line therapy, how long should therapy be prolonged, and how and when it should be tapered or discontinued after the achievement of remission. In this regard, randomized controlled trials and large series with long-term follow up are still an unmet need.

Acknowledgments
Editorial assistance was provided by Melanie Gatt (PhD), an independent medical writer, on behalf of Springer Healthcare.

Conflict of interest statement
The authors declare that there is no conflict of interest.

Funding
The authors disclose receipt of the following financial support for the research, authorship, and/or publication of this article: SOBI, Swedish Orphan Biovitrum s.r.l., provided financial support for editorial assistance.

ORCID iDs
Valerio Maniscalco \( \text{https://orcid.org/0000-0003-3287-846X} \)

Gabriele Simonini \( \text{https://orcid.org/0000-0002-5919-4861} \)

References
1. Schett G, Dayer J-M and Manger B. Interleukin-1 function and role in rheumatic disease. \textit{Nat Rev Rheumatol} 2016; 12: 14–24.

2. McDermott MF, Aksentijevich I, Galon J, \textit{et al.} Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. \textit{Cell} 1999; 97: 133–144.

3. Dinarello CA, Simon A and Van der Meer JWM. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. \textit{Nat Rev Drug Discov} 2012; 11: 633–652.

4. Newburger JW, Takahashi M, Gerber MA, \textit{et al.} Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic fever, Endocarditis and Kawasaki disease, Council on Cardiovascular Disease in the Young, American Heart Association. \textit{Circulation} 2004; 110: 2747–2771.

5. Burns JC and Glodé MP. Kawasaki syndrome. \textit{Lancet} 2004; 364: 533–544.

6. Tremoulet AH, Best BM, Song S, \textit{et al.} Resistance to intravenous immunoglobulin in children with Kawasaki disease. \textit{J Pediatr} 2008; 153: 117–121.

7. Lee Y, Schulte DJ, Shimada K, \textit{et al.} Interleukin-1β is crucial for the induction of coronary artery inflammation in a mouse model of Kawasaki disease. \textit{Circulation} 2012; 125: 1542–1550.

8. Cohen S, Tacke CE, Straver B, \textit{et al.} A child with severe relapsing Kawasaki disease rescued by IL-1 receptor blockade and extracorporeal membrane oxygenation. \textit{Ann Rheum Dis} 2012; 71: 2059–2061.

9. Sánchez-Manubens J, Gelman A, Franch N, \textit{et al.} A child with resistant Kawasaki disease successfully treated with anakinra: a case report. \textit{BMC Pediatr} 2017; 17: 102.

10. Alphonse MP, Duong TT, Shumitzu C, \textit{et al.} Inositol-triphosphate 3-kinase C mediates inflammasome activation and treatment response in Kawasaki disease. \textit{J Immunol} 2016; 197: 3481–3489.

11. Hoang LT, Shimizu C, Ling L, \textit{et al.} Global gene expression profiling identifies new therapeutic targets in acute Kawasaki disease. \textit{Genome Med} 2014; 6: 541.

12. Leung DY, Cotran RS, Kurt-Jones E, \textit{et al.} Endothelial cell activation and high interleukin-1 secretion in the pathogenesis of acute Kawasaki disease. \textit{Lancet} 1989; 2: 1298–1302.

13. Weng K-P, Ho T-Y, Chiao Y-H, \textit{et al.} Cytokine genetic polymorphisms and susceptibility to Kawasaki disease in Taiwanese children. \textit{Circ J} 2010; 74: 2726–2733.
14. Onouchi Y. The genetics of Kawasaki disease. *Int J Rheum Dis* 2018; 21: 26–30.

15. Wakita D, Kurashima Y, Crother TR, et al. Role of interleukin-1 signaling in a mouse model of Kawasaki disease-associated abdominal aortic aneurysm. *Arterioscler Thromb Vasc Biol* 2016; 36: 886–897.

16. Shafferman A, Birmingham JD and Cron RQ. High dose anakinra for treatment of severe neonatal Kawasaki disease: a case report. *Pediatr Rheumatol Online J* 2014; 12: 26.

17. Lind-Holst M, Hartling UB and Christensen, et al. Role of interleukin-1 receptor antagonist (anakinra) in idiopathic recurrent pericarditis with interleukin-1 receptor antagonist β. *Expert Opin Investig Drugs* 2016; 25: 827–840.

18. Blonz G, Lacroix S, Benbrik N, et al. Severe late-onset Kawasaki disease successfully treated with anakinra. *J Clin Rheumatol*. Epub ahead of print 15 June 2018. DOI: 10.1097/RHU.0000000000000814.

19. Guillaume M-P, Reumaux H and Dubos F. Usefulness and safety of anakinra in refractory Kawasaki disease complicated by coronary artery aneurysm. *Cardiol Young* 2018; 28: 739–742.

20. Kone-Paut I, Cimaz R, Herberg J, et al. The use of interleukin 1 receptor antagonist (anakinra) in Kawasaki disease: a retrospective cases series. *Autoimmun Rev* 2018; 17: 768–774.

21. Tremoulet AH, Jain S, Jaggi P, et al. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial. *Lancet* 2014; 383: 1731–1738.

22. Burns JC, Best BM, Mejias A, et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. *J Pediatr* 2008; 153: 833–838.

23. Imazio M, Lazaros G, Brucato A, et al. Recurrent pericarditis: new and emerging therapeutic options. *Nat Rev Cardiol* 2016; 13: 99–105.

24. Lazaros G, Antonatou K and Vassilopoulos D. The therapeutic role of interleukin-1 inhibition in idiopathic recurrent pericarditis: current evidence and future challenges. *Front Med (Lausanne)* 2017; 4: 78.

25. Picco P, Brisa G, Traverso F, et al. Successful treatment of idiopathic recurrent pericarditis in children with interleukin-1β receptor antagonist (anakinra): an unrecognized autoinflammatory disease? *Arthritis Rheum* 2009; 60: 264–268.

26. Rigante D, Cantarini L, Imazio M, et al. Autoinflammatory diseases and cardiovascular manifestations. *Ann Med* 2011; 43: 341–346.

27. Cantarini L, Lucherini OM, Brucato A, et al. Clues to detect tumor necrosis factor receptor-associated periodic syndrome (TRAPS) among patients with idiopathic recurrent acute pericarditis: results of a multicentre study. *Clin Res Cardiol* 2012; 101: 525–531.

28. Lazaros G, Imazio M, Brucato A, et al. Anakinra: an emerging option for refractory idiopathic recurrent pericarditis: a systematic review of published evidence. *J Cardiovasc Med (Hagerstown)* 2016; 17: 256–262.

29. Scardapane A, Brucato A, Chiarelli F, et al. Efficacy of an interleukin-1β receptor antagonist (anakinra) in idiopathic recurrent pericarditis. *Pediatr Cardiol* 2013; 34: 1989–1991.

30. Camacho-Lovillo M and Méndez-Santos A. Successful treatment of idiopathic recurrent pericarditis with interleukin-1 receptor antagonist (anakinra). *Pediatr Cardiol* 2013; 34: 1293–1294.

31. Finetti M, Insalaco A, Cantarini L, et al. Long-term efficacy of interleukin-1 receptor antagonist (anakinra) in corticosteroid-dependent and colchicine-resistant recurrent pericarditis. *J Pediatr* 2014; 164: 1425.e1–1431.e1.

32. Imazio M, Brucato A, Pluymaekers N, et al. Recurrent pericarditis in children and adolescents: a multicentre cohort study. *J Cardiovasc Med (Hagerstown)* 2016; 17: 707–712.

33. Brucato A, Imazio M, Gattorno M, et al. Effect of anakinra on recurrent pericarditis among patients with colchicine resistance and corticosteroid dependence: the AIRTRIP randomized clinical trial. *JAMA* 2016; 316: 1906–1912.

34. Davatchi F. Diagnosis/classification criteria for Behçet’s disease. *Pathol Res Int* 2012; 2012: 607921.

35. Koné-Paut I. Behçet’s disease in children, an overview. *Pediatr Rheumatol Online J* 2016; 14: 10.

36. Shigemura T, Kaneko N, Kobayashi N, et al. Novel heterozygous C243Y A20/TNFAIP3 gene mutation is responsible for chronic inflammation in autosomal-dominant Behçet’s disease. *RMD Open* 2016; 2: e000223.

37. Vitale A, Rigante D, Lopalco G, et al. New therapeutic solutions for Behçet’s syndrome. *Expert Opin Investig Drugs* 2016; 25: 827–840.
38. Vitale A, Insalaco A, Sfriso P, et al. A snapshot on the on-label and off-label use of the interleukin-1 inhibitors in Italy among rheumatologists and pediatric rheumatologists: a nationwide multi-center retrospective observational study. *Front Pharmacol* 2016; 7: 380.

39. Bettiol A, Silvestri E, Di Scala G, et al. The right place of interleukin-1 inhibitors in the treatment of Behçet’s syndrome: a systematic review. *Rheumatol Int* 2019; 39: 971–990.

40. Cantarini L, Vitale A, Scalini P, et al. Anakinra treatment in drug-resistant Behçet’s disease: a case series. *Clin Rheumatol* 2015; 34: 1293–1301.

41. Bilginer Y, Ayaz NA and Ozen S. Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behçet’s disease. *Clin Rheumatol* 2010; 29: 209–210.

42. Ugurlu S, Ucar D, Seyahi E, et al. Canakinumab in a patient with juvenile Behçet’s syndrome with refractory eye disease. *Ann Rheum Dis* 2012; 71: 1589–1591.

43. Sota J, Vitale A, Insalaco A, et al. Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study. *Clin Rheumatol* 2018; 37: 2233–2240.

44. Cantarini L, Talarico R, Generali E, et al. Safety profile of biologic agents for Behçet’s disease in a multicenter observational cohort study. *Int J Rheum Dis* 2017; 20: 103–108.

45. Sohar E, Gafni J, Pras M, et al. Familial Mediterranean fever. A survey of 470 cases and review of the literature. *Am J Med* 1967; 43: 227–253.

46. Tunca M, Akar S, Onen F, et al. Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. *Medicine (Baltimore)* 2005; 84: 1–11.

47. Melikoglu MA and Senel K. Non-response to colchicine in familial Mediterranean fever should be identified accurately. *Int J Rheum Dis* 2017; 20: 2118–2121.

48. Corsia A, Georgin-Lavialle S, Hentgen V, et al. A survey of resistance to colchicine treatment for French patients with familial Mediterranean fever. *Orphanet J Rare Dis* 2017; 12: 54.

49. Cercuaglia C, Diaco M, Nucera G, et al. Pharmacological and clinical basis of treatment of familial Mediterranean fever (FMF) with colchicine or analogues: an update. *Curr Drug Targets Inflamm Allergy* 2005; 4: 117–124.

50. Ben-Zvi I, Kukuy O, Giat E, et al. Anakinra for colchicine-resistant familial Mediterranean fever: a randomized, double-blind, placebo-controlled trial. *Arthritis Rheumatol* 2017; 69: 854–862.

51. Papin S, Cuenin S, Agostini L, et al. The SPRY domain of Pyrin, mutated in familial Mediterranean fever patients, interacts with inflammasome components and inhibits proIL-1beta processing. *Cell Death Differ* 2007; 14: 1457–1466.

52. Hesker PR, Nguyen M, Kovarova M, et al. Genetic loss of murine pyrin, the familial Mediterranean fever protein, increases interleukin-1β levels. *PLoS One* 2012; 7: e51105.

53. Yu J-W, Fernandes-Alnemri T, Datta P, et al. Pyrin activates the ASC pyroptosome in response to engagement by autoinflammatory PSTPIP1 mutants. *Mol Cell* 2007; 28: 214–227.

54. Van der Hilst JCH, Bodar EJ, Barron KS, et al. Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome. *Medicine (Baltimore)* 2008; 87: 301–310.

55. Roldan R, Ruiz AM, Miranda MD, et al. Anakinra: new therapeutic approach in children with familial Mediterranean fever resistant to colchicine. *Joint Bone Spine* 2008; 75: 504–505.

56. Kuijk LM, Govers AMAP, Frenkel J, et al. Effective treatment of a colchicine-resistant familial Mediterranean fever patient with anakinra. *Ann Rheum Dis* 2007; 66: 1545–1546.

57. Calligaris L, Marchetti F, Tommasini A, et al. The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever. *Eur J Pediatr* 2008; 167: 695–696.

58. Meinzer U, Quartier P, Alexandra J-F, et al. Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature. *Semin Arthritis Rheum* 2011; 41: 265–271.

59. Cetin P, Sari I, Sozeri B, et al. Efficacy of interleukin-1 targeting treatments in patients with familial Mediterranean fever. *Inflammation* 2015; 38: 27–31.

60. Ozen S, Bilginer Y, Ayaz NA, et al. Anti-interleukin 1 treatment for patients with familial Mediterranean fever resistant to colchicine. *J Rheumatol* 2011; 38: 516–518.

61. Özçakar ZB, Özdel S, Yılmaz S, et al. Anti-IL-1 treatment in familial Mediterranean fever and related amyloidosis. *Clin Rheumatol* 2016; 35: 441–446.
62. Gattorno M, Pelagatti MA, Meini A, et al. Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. *Arthritis Rheum* 2008; 58: 1516–1520.

63. Grimwood C, Despert V, Jeru I, et al. On-demand treatment with anakinra: a treatment option for selected TRAPS patients. *Rheumatology (Oxford)* 2015; 54: 1749–1751.

64. Rigante D, Ansuini V, Bertoni B, et al. Treatment with anakinra in the hyperimmunoglobulinemia D/periodic fever syndrome. *Rheumatol Int* 2006; 27: 97–100.

65. Nevyjel M, Pontillo A, Calligaris L, et al. Diagnostics and therapeutic insights in a severe case of mevalonate kinase deficiency. *Pediatrics* 2007; 119: e523–e527.

66. Korppi M, Van Gin ME and Antila K. Hyper-immunoglobulinemia D and periodic fever syndrome in children. Review on therapy with biological drugs and case report. *Acta Paediatr* 2011; 100: 21–25.

67. Bodar EJ, Kuijk LM Drenth JPH, et al. On-demand anakinra treatment is effective in mevalonate kinase deficiency. *Ann Rheum Dis* 2011; 70: 2155–2158.

68. Galeotti C, Meinzner U, Quartier P, et al. Efficacy of interleukin-1-targeting drugs in mevalonate kinase deficiency. *Rheumatology (Oxford)* 2012; 51: 1855–1859.

69. Shendi HM, Walsh D and Edgar JDM. Etanercept and anakinra can prolong febrile episodes in patients with hyperimmunoglobulinin D and periodic fever syndrome. *Rheumatol Int* 2012; 32: 249–251.

70. Levy M, Arion A, Berrebi D, et al. Severe early-onset colitis revealing mevalonate kinase deficiency. *Pediatrics* 2013; 132: e779–e783.

71. Campanilho-Marques R and Brogan PA. Mevalonate kinase deficiency in two sisters with therapeutic response to anakinra: case report and review of the literature. *Clin Rheumatol* 2014; 33: 1681–1684.

72. Santos JA, Aróstegui JJ, Brito MJ, et al. Hyper-IgD and periodic fever syndrome: a new MVK mutation (p.R277G) associated with a severe phenotype. *Gene* 2014; 542: 217–220.

73. Kostjukovits S, Kalliokoski L, Antila K, et al. Treatment of hyperimmunoglobulinemia D syndrome with biologics in children: review of the literature and Finnish experience. *Eur J Pediatr* 2015; 174: 707–714.

74. Garg S, Wynne K, Omoyinni E, et al. Efficacy and safety of anakinra for undifferentiated autoinflammatory diseases in children: a retrospective case review. *Rheumatol Adv Pract* 2019; 3: rkz004.

75. Özen S, Kuemmerle-Deschner JB, Cimaz R, et al. International retrospective chart review of treatment patterns in severe familial Mediterranean fever, tumor necrosis factor receptor-associated periodic syndrome, and mevalonate kinase deficiency/hyperimmunoglobulinemia D syndrome. *Arthritis Care Res (Hoboken)* 2017; 69: 578–586.

76. Dodé C, André M, Bienvenu T, et al. The enlarging clinical, genetic, and population spectrum of tumor necrosis factor receptor-associated periodic syndrome. *Arthritis Rheum* 2002; 46: 2181–2188.

77. Rigante D, Lopalco G, Vitale A, et al. Key facts and hot spots on tumor necrosis factor receptor-associated periodic syndrome. *Clin Rheumatol* 2014; 33: 1197–1207.

78. Cantarini L, Lucherini OM, Muscari I, et al. Tumour necrosis factor receptor-associated periodic syndrome (TRAPS): state of the art and future perspectives. *Autoimmun Rev* 2012; 12: 38–43.

79. Ter Haar N, Lachmann H, Özen S, et al. Treatment of autoinflammatory diseases: results from the Eurofever registry and a literature review. *Ann Rheum Dis* 2013; 72: 678–685.

80. Bulua AC, Mogul DB, Aksentijevich I, et al. Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome: a prospective, open-label, dose-escalation study. *Arthritis Rheum* 2012; 64: 908–913.

81. De Benedetti F, Gattorno M, Anton J, et al. Canakinumab for the treatment of autoinflammatory recurrent fever syndromes. *N Engl J Med* 2018; 378: 1908–1919.

82. Gattorno M, Obici L, Catalini M, et al. Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study. *Ann Rheum Dis* 2017; 76: 173–178.

83. Houten SM, Kuis W, Duran M, et al. Mutations in MVK, encoding mevalonate kinase, cause hyperimmunoglobulinemia D and periodic fever syndrome. *Nat Genet* 1999; 22: 175–177.

84. Hoffmann GF, Charpentier C, Mayatepek E, et al. Clinical and biochemical phenotype in 11 patients with mevalonic aciduria. *Pediatrics* 1993; 91: 915–921.
85. Harrison SR, McGonagle D, Nizam S, et al. Anakinra as a diagnostic challenge and treatment option for systemic autoinflammatory disorders of undefined etiology. JCI Insight 2016; 1: e86336.

86. Girschick H, Finetti M, Orlando F, et al. The multifaceted presentation of chronic recurrent multifocal osteomyelitis: a series of 486 cases from the Eurofever international registry. Rheumatology (Oxford) 2018; 57: 1203–1211.

87. Hofmann SR, Schwarz T, Möller JC, et al. Chronic non-bacterial osteomyelitis is associated with impaired Sp1 signaling, reduced IL10 promoter phosphorylation, and reduced myeloid IL-10 expression. Clin Immunol 2011; 141: 317–327.

88. Eleftheriou D, Gerschman T, Sebire N, et al. Biologic therapy in refractory chronic non-bacterial osteomyelitis of childhood. Rheumatology (Oxford) 2010; 49: 1505–1512.

89. Pardeo M, Marafon DP, Messia V, et al. Anakinra in a cohort of children with chronic non-bacterial osteomyelitis. J Rheumatol 2017; 44: 1231–1238.

90. Herlin T, Fijirgaard B, Bjerre M, et al. Efficacy of anti-IL-1 treatment in Majeed syndrome. Ann Rheum Dis 2013; 72: 410–413.

91. Ferguson PJ, Chen S, Tayeh MK, et al. Homozygous mutations in LPIN2 are responsible for the syndrome of chronic recurrent multifocal osteomyelitis and congenital dyserythropoietic anaemia (Majeed syndrome). J Med Genet 2005; 42: 551–557.

92. Akstentievich I, Masters SL, Ferguson PJ, et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med 2009; 360: 2426–2437.

93. Ravelli A, Minoia F, Davi S, et al. Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation collaborative initiative. Ann Rheum Dis 2016; 75: 481–489.

94. Ravelli A, Grom AA, Behrens EM, et al. Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. Genes Immun 2012; 13: 289–298.

95. Durand M, Troyanov Y, Laflamme P, et al. Macrophage activation syndrome treated with anakinra. J Rheumatol 2010; 37: 879–880.

96. Rigante D, Emmi G, Fastiggi M, et al. Macrophage activation syndrome in the course of monogenic autoinflammatory disorders. Clin Rheumatol 2015; 34: 1333–1339.

97. Rigante D, Capoluongo E, Bertoni B, et al. First report of macrophage activation syndrome in hyperimmunoglobulinemia D with periodic fever syndrome. Arthritis Rheum 2007; 56: 658–661.

98. Horneff G, Rhouma A, Weber C, et al. Macrophage activation syndrome as the initial manifestation of tumour necrosis factor receptor 1-associated periodic syndrome (TRAPS). Clin Exp Rheumatol 2013; 31(3 Suppl. 77): 99–102.

99. Rossi-Semerano L, Hermeziu B, Fabre M, et al. Macrophage activation syndrome revealing familial Mediterranean fever. Arthritis Care Res (Hoboken) 2011; 63: 780–783.

100. Sawhney S, Woo P and Murray KJ. Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch Dis Child 2001; 85: 421–426.

101. Kahn PF and Cron RQ. Higher-Dose anakinra is effective in a case of medically refractory macrophage activation syndrome. J Rheumatol 2013; 40: 743–744.

102. Butin M, Mekki Y, Phan A, et al. Successful immunotherapy in life-threatening parvovirus B19 infection in a child. Pediatr Infect Dis J 2013; 32: 789–792.

103. Aytaç S, Batu ED, Ünal Ş, et al. Macrophage activation syndrome in children with systemic juvenile idiopathic arthritis and systemic lupus erythematosus. Rheumatol Int 2016; 36: 1421–1429.

104. Barsalou J, Blincoe A, Fernandez I, et al. Rapamycin as an adjunctive therapy for NLRC4 associated macrophage activation syndrome. Front Immunol 2018; 9: 2162.

105. Sönmez HE, Demir S, Bilginer Y, et al. Anakinra treatment in macrophage activation syndrome: a single center experience and systemic review of literature. Clin Rheumatol 2018; 37: 3329–3335.

106. Miettunen PM, Narendran A, Jayanthan A, et al. Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients. Rheumatology (Oxford) 2011; 50: 417–419.

107. Kelly A and Ramanan AV. A case of macrophage activation syndrome successfully treated with anakinra. Nat Clin Pract Rheumatol 2008; 4: 615–620.
108. Bruck N, Suttorp M, Kabus M, et al. Rapid and sustained remission of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome through treatment with anakinra and corticosteroids. *J Clin Rheumatol* 2011; 17: 23–27.

109. Lilleby V, Haydon J, Sanner H, et al. Severe macrophage activation syndrome and central nervous system involvement in juvenile dermatomyositis. *Scand J Rheumatol* 2014; 43: 171–173.

110. Rajasekaran S, Kruse K, Kovey K, et al. Therapeutic role of anakinra, an interleukin-1 receptor antagonist, in the management of secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction/macrophase activating syndrome in critically ill children*. *Pediatr Crit Care Med* 2014; 15: 401–408.

111. Eloseily EM, Weiser P, Crayne CB, et al. Benefit of anakinra in treating pediatric secondary hemophagocytic lymphohistiocytosis. *Arthritis Rheumatol* 2020; 72: 326–334.

112. Karakike E and Giamarellos-Bourboulis EJ. Macrophage activation-like syndrome: a distinct entity leading to early death in sepsis. *Front Immunol* 2019; 10: 55.

113. Simon DW, Aneja R, Carcillo JA, et al. Plasma exchange, methylprednisolone, IV immune globulin, and now anakinra support continued PICU equipoise in management of hyperferritinemia-associated sepsis/multiple organ dysfunction syndrome/macrophase activation syndrome/secondary hemophagocytic lymphohistiocytosis syndrome*. *Pediatr Crit Care Med* 2014; 15: 486–488.

114. Nigrovic PA, Mannion M, Prince FHM, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. *Arthritis Rheum* 2011; 63: 545–555.

115. Zeft A, Hollister R, LaFleur B, et al. Anakinra for systemic juvenile arthritis: the Rocky Mountain experience. *J Clin Rheumatol* 2009; 15: 161–164.

116. Hirsch LJ, Gaspard N, Van Baalen A, et al. Proposed consensus definitions for new-onset refractory status epilepticus (NORSE), febrile infection-related epilepsy syndrome (FIRES), and related conditions. *Epilepsia* 2018; 59: 739–744.

117. Van Baalen A, Häusler M, Plecko-Startinig B, et al. Febrile infection-related epilepsy syndrome without detectable autoantibodies and response to immunotherapy: a case series and discussion of epileptogenesis in FIRES. *Neuropediatrics* 2012; 43: 209–216.

118. Lam S-K, Lu W-Y, Weng W-C, et al. The short-term and long-term outcome of febrile infection-related epilepsy syndrome in children. *Epilepsy Behav* 2019; 95: 117–123.

119. Hon KL, Leung AKC and Torres AR. Febrile infection-related epilepsy syndrome (FIRES): an overview of treatment and recent patents. *Recent Pat Inflamm Allergy Drug Discov* 2018; 12: 128–135.

120. Fox K, Wells ME, Tennison M, et al. Febrile infection-related epilepsy syndrome (FIRES): a literature review and case study. *Neurodiagn J* 2017; 57: 224–233.

121. Serino D, Santarone ME, Caputo D, et al. Febrile infection-related epilepsy syndrome (FIRES): prevalence, impact and management strategies. *Neuropsychiatr Dis Treat* 2019; 15: 1897–1903.

122. Terrone G, Frigerio F, Balosso S, et al. Inflammation and reactive oxygen species in status epilepticus: biomarkers and implications for therapy. *Epilepsy Behav* 2019; 101: 106275.

123. Dubé C, Vezzani A, Behrens M, et al. Interleukin-1beta contributes to the generation of experimental febrile seizures. *Ann Neurol* 2005; 57: 152–155.

124. Clarkson BDS, LaFrance-Corey RG, Kahoud RJ, et al. Functional deficiency in endogenous interleukin-1 receptor antagonist in patients with febrile infection-related epilepsy syndrome. *Ann Neurol* 2019; 85: 526–537.

125. Kenney-Jung DL, Vezzani A, Kahoud RJ, et al. Febrile infection-related epilepsy syndrome treated with anakinra. *Ann Neurol* 2016; 80: 939–945.

126. Shukla N, Risen S, Erklauer J, et al. Anakinra (IL-1 blockade) use in children with suspected FIRES: a single institution experience. *Neurol* 2018; 90: 346.

127. Dilena R, Mauiri E, Aronica E, et al. Therapeutic effect of anakinra in the relapsing chronic phase of febrile infection-related epilepsy syndrome. *Epilepsia Open* 2019; 4: 344–350.

128. DeSena AD, Do T and Schulert GS. Systemic autoinflammation with intractable epilepsy managed with interleukin-1 blockade. *J Neuroinflammation* 2018; 15: 38.

129. Sa M, Singh R, Pujar S, et al. Centromedian thalamic nuclei deep brain stimulation and anakinra treatment for FIRES - two different approaches.
outcomes. *Eur J Paediatr Neurol* 2019; 23: 749–754.

130. Aksentijevich I and McDermott MF. Lessons from characterization and treatment of the autoinflammatory syndromes. *Curr Opin Rheumatol* 2017; 29: 187–194.

131. Ter Haar NM, Annink KV, Al-Mayouf SM, et al. Development of the autoinflammatory disease damage index (ADDI). *Ann Rheum Dis* 2017; 76: 821–830.

132. Fleischmann RM, Tesser J, Schiff MH, et al. Safety of extended treatment with anakinra in patients with rheumatoid arthritis. *Ann Rheum Dis* 2006; 65: 1006–1012.

133. Henderson LA and Cron RQ. Macrophage activation syndrome and secondary hemophagocytic lymphohistiocytosis in childhood inflammatory disorders: diagnosis and management. *Paediatr Drugs* 2020; 22: 29–44.